Document Classification

Section Type: RESULTS

Text: For the primary outcome of modified Alzheimer 's Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) scores at 12weeks of follow-up, the odds of being at or better than a given mADCS-CGIC category did not significantly differ between the two treatment groups for those patients with MaD at baseline (OR (sertraline) = 0. 66 [95 % CI : 0. 24, 1. 82], p = 0. 42) ; tests for interactions between treatment group and baseline depression diagnostic subgroup were not significant for MaD versus MiD versus neither ((2) = 1. 05 (2df), p = 0. 59) or AAAD versus no AAAD ((2) = 0. 06 (1df), p = 0. 81).